Novan, Inc. (NOVN)
| Market Cap | 151.02M |
| Revenue (ttm) | 4.53M |
| Net Income (ttm) | -32.08M |
| Shares Out | 15.00M |
| EPS (ttm) | -2.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $7.48 |
| Previous Close | $8.03 |
| Change ($) | -0.55 |
| Change (%) | -6.85% |
| Day's Open | 8.09 |
| Day's Range | 7.48 - 8.14 |
| Day's Volume | 882,919 |
| 52-Week Range | 3.00 - 25.90 |
– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less than ...
CHICAGO--(BUSINESS WIRE)--Pritzker Private Capital (“PPC”), a leader in family direct investing, today announced the appointment of Paula Brown Stafford to the Pritzker Advisory Board. Ms. Stafford, cur...
DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that as part of the annual reconstitution of the Russell stock indexes, Novan has b...
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering (the “...
Novan Inc (NASDAQ: NOVN) priced its previously announced public offering of 3.6 million shares at $11/share for gross proceeds of approximately $40 million. The offer price represents a 21% discount on ...
DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering (the “...
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”). All sh...
Are these former penny stocks on your watch list right now? The post 4 Penny Stocks To Watch Hit It Big In 2021, 1 Up Over 2,200% Right Now appeared first on Penny Stocks to Buy, Picks, News and Informa...
NOVN stock is flexing 70% gains as the company shows off the wild success of its topical treatment for a common, contagious infection. The post NOVN Stock: The Positive Trial Results Sending Novan Skyro...
Novan Inc. (NASDAQ: NOVN) shares are trading higher Friday after the company reported that B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved significance for the primary endpoint with no adverse events....
Novan Inc (NASDAQ:NOVN) shares are trading higher by 59% at $14.37 Friday morning after the company reported the B-SIMPLE4 pivotal Phase 3 trial of SB206 achieved statistical significance for the primar...
Novan Inc (NASDAQ: NOVN) has announced positive topline efficacy and safety results from the B-SIMPLE4 Phase 3 trial evaluating SB206, a topical antiviral gel, for the treatment of molluscum contagiosum...
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 –
– Data indicate that berdazimer sodium prevents progression of SARS-CoV-2 infection in two independent in vivo transmission studies –
– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action –
Biotech penny stocks are heating up right now; here's 4 to watch The post Best Biotech Penny Stocks to Buy Under $5? 4 To Check Out in May appeared first on Penny Stocks to Buy, Picks, News and Informat...
– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 –
– Topline data on track for readout before the end of Q2 2021 –
MORRISVILLE, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, wi...
– B-SIMPLE4 pivotal Phase 3 trial evaluating SB206 as a treatment for molluscum contagiosum progressing with top-line efficacy results targeted before the end of Q2 2021 –
– Topline data on track for targeted readout before the end of Q2 2021 –
MORRISVILLE, N.C., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has received written notice from The Nasdaq Stock Market LLC (“Nasdaq”...
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 –
NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, wil...
– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing –
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 –
NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty cl...
– T rading on Nasdaq Capital Market is expected to begin on November 5, 2020 –
– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 –
- Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET - Live moderated video webcast d...
- F irst demonstration of antiviral effect of nitric oxide -based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium
- John M. Gay , V ice P resident , Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer
- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -
- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT -
- Topline results targeted for Q2 2021, less than a year away -
- Clinical sites actively enrolling patients -
MORRISVILLE, N.C., July 28, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced an expanded role of Paula Brown Stafford, President and Chief Executive O...
MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annual Meeting ...
MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be sufficient...
MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executive Officer...
MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has received meeting minutes from the April 1, 2020 Type C m...
MORRISVILLE, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that it has engaged H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) to a...
Top Ranked Momentum Stocks to Buy for April 6th
MORRISVILLE, N.C., April 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Food and Drug...
Top Ranked Momentum Stocks to Buy for April 2nd
Top Ranked Momentum Stocks to Buy for March 30th
MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct offering ...
MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional and...
MORRISVILLE, N.C., March 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced data from the prospectively planned safety evaluation through Week 24 as part...
About NOVN
Novan, Inc., a clinical development-stage biotechnology company, provides nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-base... [Read more...]
| Industry Biotechnology | IPO Date Sep 21, 2016 |
| CEO Paula Stafford | Employees 23 |
| Stock Exchange NASDAQ | Ticker Symbol NOVN |
Financial Performance
In 2020, Novan's revenue was $4.92 million, an increase of 0.49% compared to the previous year's $4.90 million. Losses were -$29.29 million, -3.57% less than in 2019.
Analyst Forecasts
According to one analyst, the rating for Novan stock is "Buy" and the 12-month stock price forecast is 47.00.